EA201170249A1 - 3,4-diarilpyrazole as a proteinkinaz inhibitor - Google Patents

3,4-diarilpyrazole as a proteinkinaz inhibitor

Info

Publication number
EA201170249A1
EA201170249A1 EA201170249A EA201170249A EA201170249A1 EA 201170249 A1 EA201170249 A1 EA 201170249A1 EA 201170249 A EA201170249 A EA 201170249A EA 201170249 A EA201170249 A EA 201170249A EA 201170249 A1 EA201170249 A1 EA 201170249A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diarilpyrazole
proteinkinaz
inhibitor
diarylpyrazole
therapy
Prior art date
Application number
EA201170249A
Other languages
Russian (ru)
Other versions
EA019722B1 (en
Inventor
Маурицио Пуличи
Фабио Дзуккотто
Алессандра Бадари
Стефано Нуволони
Джованни Черви
Габриелла Тракванди
Соня Бьондаро
Паоло Трифиро'
Кьяра Маркионни
Микеле Модуньо
Original Assignee
НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to EP08161076 priority Critical
Application filed by НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. filed Critical НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.
Priority to PCT/EP2009/059506 priority patent/WO2010010154A1/en
Publication of EA201170249A1 publication Critical patent/EA201170249A1/en
Publication of EA019722B1 publication Critical patent/EA019722B1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41059486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201170249(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems

Abstract

Derivatives of 3,4-diarylpyrazole of the formula (I) as defined herein and their pharmaceutically acceptable salts, a process for their preparation and pharmaceutical compositions containing them are disclosed; the compounds of the invention may be useful in therapy, treatment of diseases associated with impaired regulation of protein kinase activity, like a malignant tumor.
EA201170249A 2008-07-24 2009-07-23 3,4-diarylpyrazoles as protein kinase inhibitors EA019722B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP08161076 2008-07-24
PCT/EP2009/059506 WO2010010154A1 (en) 2008-07-24 2009-07-23 3,4-diarylpyrazoles as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201170249A1 true EA201170249A1 (en) 2011-10-31
EA019722B1 EA019722B1 (en) 2014-05-30

Family

ID=41059486

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170249A EA019722B1 (en) 2008-07-24 2009-07-23 3,4-diarylpyrazoles as protein kinase inhibitors

Country Status (19)

Country Link
US (2) US8541575B2 (en)
EP (1) EP2324008B1 (en)
JP (1) JP5385382B2 (en)
CN (1) CN102105459B (en)
AT (1) AT557015T (en)
AU (1) AU2009273197B2 (en)
CA (1) CA2731146C (en)
CL (1) CL2011000124A1 (en)
CY (1) CY1117667T1 (en)
DK (1) DK2324008T3 (en)
EA (1) EA019722B1 (en)
ES (1) ES2386408T3 (en)
HK (1) HK1157337A1 (en)
HR (1) HRP20120577T1 (en)
MX (1) MX2011000738A (en)
PL (1) PL2324008T3 (en)
PT (1) PT2324008E (en)
SI (1) SI2324008T1 (en)
WO (1) WO2010010154A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090837A1 (en) 2007-07-02 2009-07-24 Boehringer Ingelheim Int New chemical compounds
CN102083312B (en) 2008-05-06 2014-08-27 葛兰素史密丝克莱恩有限责任公司 Benzene sulfonamide thiazole and oxazole compounds
MX2011000738A (en) * 2008-07-24 2011-02-23 Nerviano Medical Sciences Srl 3,4-diarylpyrazoles as protein kinase inhibitors.
AU2009295855A1 (en) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh Antiproliferative compounds
JP2011057661A (en) * 2009-08-14 2011-03-24 Bayer Cropscience Ag Pesticidal carboxamides
AR077975A1 (en) 2009-08-28 2011-10-05 Irm Llc PIRAZOL PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AU2011209234B2 (en) 2010-01-27 2015-05-07 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
JP5871896B2 (en) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング B-RAF kinase inhibitor
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
AR081810A1 (en) 2010-04-07 2012-10-24 Bayer Cropscience Ag BICYCLE PIRIDINYL PIRAZOLS
BR112012032884A2 (en) * 2010-06-25 2016-11-08 Novartis Ag heteroaryl compounds and compositions as protein kinase inhibitors
US9114137B2 (en) 2010-08-03 2015-08-25 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
TWI480276B (en) * 2010-08-27 2015-04-11 Irm Llc Compounds and compositions as protein kinase inhibitors
US8710055B2 (en) * 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
JP5998152B2 (en) * 2011-01-25 2016-09-28 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン BCL-2 / BCL-XL inhibitor and therapeutic method using the same
US9199979B2 (en) 2011-02-24 2015-12-01 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
KR101298651B1 (en) * 2011-03-16 2013-08-21 연세대학교 산학협력단 Pharmaceutical Compositions for Enhanced Anti-angiogenic Activities
RU2627272C2 (en) 2011-10-06 2017-08-04 Байер Интеллектчуал Проперти Гмбх Heterocyclyl pyridinylpyrazoles
DK2763987T3 (en) 2011-10-06 2018-10-15 Bayer Cropscience Ag Heterocyclylpyry (mi) dinylpyrazole as fungicider
EA025389B1 (en) 2011-11-23 2016-12-30 Новартис Аг Pharmaceutical formulations
EP2914586B1 (en) 2012-11-02 2017-04-05 Pfizer Inc Bruton's tyrosine kinase inhibitors
CN110302205B (en) 2013-01-16 2020-06-09 密歇根大学董事会 Medical application of BCL-2/Bcl-xL inhibitor and pharmaceutical composition thereof
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag Compounds and compositions as kinase inhibitors
US10822337B2 (en) 2015-04-01 2020-11-03 Rigel Pharmaceuticals, Inc. TGF-β inhibitorC
MX2018003351A (en) 2015-09-16 2018-09-17 Loxo Oncology Inc Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer.
KR20180115261A (en) * 2015-12-16 2018-10-22 록쏘 온콜로지, 인코포레이티드 Compound useful as a kinase inhibitor
JP6805336B2 (en) 2016-06-03 2020-12-23 アレイ バイオファーマ、インコーポレイテッド Pharmaceutical combination
CN106883266B (en) * 2017-01-23 2020-03-17 江苏七洲绿色化工股份有限公司 Preparation method of 1- (4-chlorphenyl) -2-cyclopropyl-1-acetone and intermediate thereof
WO2019081477A1 (en) 2017-10-26 2019-05-02 Bayer Cropscience Aktiengesellschaft Substituted pyrazoles, salts thereof and use thereof as herbicidal agents
WO2019081485A1 (en) 2017-10-26 2019-05-02 Bayer Cropscience Aktiengesellschaft Substituted pyrazoles, salts thereof and use thereof as herbicidal agents
WO2020087024A1 (en) * 2018-10-26 2020-04-30 Arrien Pharmaceuticals Llc Pyrazolyl compounds and methods of use thereof
WO2020245044A1 (en) 2019-06-03 2020-12-10 Bayer Aktiengesellschaft 1-phenyl-5-azinyl pyrazolyl-3-oxyalkyl acids and their use for controlling undesired plant growth

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
BR9809147A (en) 1997-05-22 2000-08-01 Searle & Co Substituted pyrazole compound, pharmaceutical composition, processes for treating a tnf mediated disorder, a p38 kinase mediated disorder, inflammation and arthritis, and for preparing pyrazoles
EP1456180B1 (en) 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use
JP2007517825A (en) * 2004-01-09 2007-07-05 ノバルティス アクチエンゲゼルシャフト Phenyl- [4- (3-phenyl-1H-pyrazol-4-yl) -pyrimidin-2-yl] -amine derivatives as IGF-IR inhibitors
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
JP2009530261A (en) * 2006-03-16 2009-08-27 ファイザー・プロダクツ・インク Pyrazole compounds
CN103739595A (en) * 2006-10-02 2014-04-23 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
MX2011000738A (en) * 2008-07-24 2011-02-23 Nerviano Medical Sciences Srl 3,4-diarylpyrazoles as protein kinase inhibitors.
AU2011209234B2 (en) * 2010-01-27 2015-05-07 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
US9114137B2 (en) 2010-08-03 2015-08-25 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents

Also Published As

Publication number Publication date
CY1117667T1 (en) 2017-05-17
AT557015T (en) 2012-05-15
ES2386408T3 (en) 2012-08-20
MX2011000738A (en) 2011-02-23
CL2011000124A1 (en) 2011-05-06
JP5385382B2 (en) 2014-01-08
DK2324008T3 (en) 2012-07-23
PL2324008T3 (en) 2012-09-28
US20110144068A1 (en) 2011-06-16
EA019722B1 (en) 2014-05-30
SI2324008T1 (en) 2012-08-31
WO2010010154A1 (en) 2010-01-28
JP2011528698A (en) 2011-11-24
EP2324008B1 (en) 2012-05-09
AU2009273197B2 (en) 2014-01-16
US20140005150A1 (en) 2014-01-02
US8946250B2 (en) 2015-02-03
CN102105459B (en) 2014-09-10
CN102105459A (en) 2011-06-22
EP2324008A1 (en) 2011-05-25
AU2009273197A1 (en) 2010-01-28
HK1157337A1 (en) 2012-06-29
US8541575B2 (en) 2013-09-24
CA2731146C (en) 2016-05-03
PT2324008E (en) 2012-06-25
AU2009273197A2 (en) 2011-03-10
CA2731146A1 (en) 2010-01-28
HRP20120577T1 (en) 2012-08-31

Similar Documents

Publication Publication Date Title
RU2470918C2 (en) NOVEL INDOLE DERIVATIVES HAVING IκB KINASE β INHIBITING ACTIVITY
CY1116882T1 (en) Imidazolotheiadiazolia for use as protein kinase inhibitors
EA201991884A2 (en) G12c kras inhibitors
CY1120088T1 (en) AZAZINE OR DIAZANDAZOLO TYPE PRODUCTS AS MEDICINE
EA201592256A1 (en) Derivatives of imidazopirrolidinone and their application in the treatment of diseases
NZ630457A (en) Compounds useful as inhibitors of atr kinase
BR112015014585A2 (en) compound, pharmaceutical composition, and method of treating a human
CY1116929T1 (en) Pyrrolo [2,3-D] Pyrimidine Derivatives as Protein Kinase Inhibitors B
EA201691151A1 (en) CONNECTIONS FOR THE TREATMENT OF PATIENTS WITH ROS1-MUTANT CANCER CELLS
BR112015028879A8 (en) heterocyclic derivative compounds, pharmaceutical composition comprising said compounds and uses thereof
HRP20131051T1 (en) Protein kinase inhibitors
BR112014015720A2 (en) thieno [3,2-d] pyrimidine derivatives having protein kinase inhibitory activity
NZ700761A (en) Salt form of a human histone methyltransferase ezh2 inhibitor
BR112014001801A2 (en) Indazoles
BR112012017123A2 (en) n- (1h-indazol-4-yl) imidazo [1,2-a] pyridin-3-carboxamide compound as cfms inhibitors
BR112014027181A2 (en) benzamide derivatives for inhibition of abl1, abl2 and bcr-abl1 activity
CO6390066A2 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
BR112014012129A2 (en) heterocyclic glutaminase inhibitors
EA201270480A1 (en) New connections
EA201290237A1 (en) Kinase inhibitors
BR112012009215A2 (en) "cancer combined therapy with hsp90 inhibitor compounds"
MX2010014233A (en) Chemical compounds 251.
IL229136D0 (en) Mek inhibitors and methods of their use
BRPI0513843A (en) compound or a pharmaceutically acceptable salt or solvate or prodrug thereof, pharmaceutical composition, dosage form, use of a compound, and hydrochloride salt
EA201491356A1 (en) Proteinkinaz inhibitors (options), their application for the treatment of oncological diseases and pharmaceutical composition on their basis

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM